The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
Year: 2003
Type: article
Source: Leukemia
Institutions: European Organisation for Research and Treatment of Cancer, European Organisation for Research and Treatment of Cancer, Universitair Ziekenhuis Leuven, University Hospital Centre Zagreb, Hôpital Edouard Herriot, Heinrich Heine University Düsseldorf, Saint John's Hospital, AZ Sint-Jan, Cliniques Universitaires Saint-Luc, Sapienza University of Rome, St. Eugenio Hospital, LMU Klinikum, Ludwig-Maximilians-Universität München, Hôtel-Dieu de Paris, Kantonsspital St. Gallen, Leiden University Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W2011302230